Boceprevir (Victrelis) Approved for Hepatitis C

Longer Interferon Treatment Raises Hepatitis C Cure Rate

Meta-analysis finds that extending pegylated interferon plus ribavirin to 72 weeks may improve sustained response rates for late-responder genotype 1 hepatitis C patients.

Screen for HCV Based on Age, Not Risk Factors

EASL Releases New Hepatitis C Clinical Practice Guidelines

EASL updates European guidelines for management of patients with acute and chronic hepatitis C virus (HCV) infection.

Is Hepatitis C Rising among Young People?

Massachusetts surveillance data showed an increase in hepatitis C among adolescents and young adults during 2002-2009, thought to be largely attributable to injection drug use.

FDA Committee Unanimously Recommends Telaprevir (Incivek)

The FDA Antiviral Drugs Advisory Committee last week voted 18-0 to recommend approval of the HCV protease inhibitor telaprevir (Incivek) for people with genotype 1 chronic hepatitis C.

Prenatal HBV Screening Helps Babies More than Moms

Routine screening for hepatitis B virus (HBV) during pregnancy enables most infants to be protected against infection, but underserved mothers often do not receive education about or care for their own infection, researchers reported this week at DDW 2011.

Boceprevir for HCV Wins Unanimous FDA Committee Recommendation

FDA Antiviral Drugs Advisory Committee voted 18-0 to recommend approval of protease inhibitor boceprevir (Victrelis) for people with hard-to-treat HCV genotype 1.